Abstracts Archive - Page 1575 of 2425 - ACR Meeting Abstracts

Abstract Number: 2368 • 2016 ACR/ARHP Annual Meeting
Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Vibeke Strand¹, Christopher J. Swearingen², Ismail Simsek², Anita DiFrancesco², Jeymi Tambiah² and Yusuf Yazici², ¹Stanford University School of Medicine, Palo Alto, CA, ²Samumed, LLC, San Diego, CA
Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional impairment, disability, and joint space narrowing due to degradation of articular cartilage and bone remodeling. The…
Abstract Number: 2369 • 2016 ACR/ARHP Annual Meeting
Obesity and Severity of Joint Space Narrowing Are Associated with Viscosupplementation Failure in Patients with Knee Osteoarthritis. Post-Hoc Analysis of a Double-Blind, Controlled, Multicentre, Randomized Trial
Florent Eymard¹, Xavier Chevalier² and Thierry Conrozier³, ¹Department of Rheumatology, APHP Henri Mondor Hospital, Paris, France, ²Rheumatology, Hopital Henri Mondor, Créteil, France, ³Department of Rheumatology,, Nord Franche-Comté Hospital, Belfort, France
Background/Purpose: Viscosupplementation (VS) is still controversial. One of the key points is the lack of well-identified factors of response. We aimed to identify clinical…
Abstract Number: 2370 • 2016 ACR/ARHP Annual Meeting
Factors Affecting Interval Changes in Perceived Fatigue over Five Years in Patients with Rheumatoid Arthritis Compared with Osteoarthritis
Simon Stebbings^1,2, Gareth Treharne³, J. Haxby Abbott⁴ and Andrew Gray⁵, ¹Dunedin Hospital, Department of Rheumatology, Dunedin, New Zealand, ²Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, ³Psychology, University of Otago, Dunedin, New Zealand, ⁴Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand, ⁵Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
Background/Purpose: In a previous cross-sectional study we noted higher fatigue levels in patients with advanced lower limb OA compared with RA, and identified differences in…
Abstract Number: 2371 • 2016 ACR/ARHP Annual Meeting
Effect of Etanercept on Several Soluble Biomarkers in a Randomized Controlled Trial of Patients with Erosive Hand Osteoarthritis
Féline Kroon¹, Ruth Wittoek², Wing-Yee Kwok¹, Klaus Bobacz³, Dirk Elewaut², Marta Favero⁴, Tom Huizinga⁵, Josef Smolen³, Bert Vander Cruyssen², Ron Wolterbeek⁶, Leonardo Punzi⁷, Gust Verbruggen², Margreet Kloppenburg⁸ and Roberta Ramonda⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatology Unit,Department of Medicine–DIMED, University of Padova, Rheumatology Unit,University of Padova, Padova, Italy, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁸Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Erosive hand osteoarthritis (OA) is a hand OA subset with high disease burden, although effective therapies are still lacking and clinical trials are scarce.…
Abstract Number: 2372 • 2016 ACR/ARHP Annual Meeting
Effect of Oxytocin on Osteoarthritis
christian roux¹, astrid pinzano², didier Pisani³, Patricia panaia-Ferrari⁴, eric Fontas⁵, hedi Ben Yahia⁶, damien ambrosetti⁷, jean-François michiels⁸, veronique Breuil⁹ and ez Zoubir Amri¹⁰, ¹Rheumatology, LAMHESS laboratory, sofia antipolis university, CHU Pasteur 2, Nice, France, nice, France, ²IMoPA Ingénierie Moléculaire et Physiopathologie Articulaire, University nancy lorraine, UMR7365 CNRS-UL, Nancy, France, ³CNRS UMR7277, Inserm U1091, UNS Université Nice Sophia Antipolis Parc Valrose, nice, France, ⁴IBiology and immunology laboratory, university nice sofia antipolis, nice, France, ⁵Direction recherche clinique, CHU de Nice, france, Nice, France, ⁶iBV - Institut de Biologie Valrose. Nice, Nice, France, ⁷Department anatomopathology, nice. university nice sofia antipolis, nice, France, ⁸department anatomo-pathology, Nice, university nice sofia antipolis, Nice, France, ⁹Rheumatology department, Nice, France, ¹⁰CNRS UMR7277, Inserm U1091, UNS Université Nice Sophia Antipolis Parc Valrose, Nice, France
Background/Purpose: The relationship between oxytocine (OT) and osteoarthritis (OA) is poorly studied and remains unknown. However the subchondral bone is considered as a major player in…
Abstract Number: 2373 • 2016 ACR/ARHP Annual Meeting
Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Laura Khurana¹, Ellen Durand¹, Sarah Gary¹, Tony Otero¹, Chris Hall¹, Aisling Ryan², Christopher J. Evans² and Susan Dallabrida¹, ¹ERT, Boston, MA, ²Endpoint Outcomes, Boston, MA
Background/Purpose: Electronic patient-reported outcomes (ePROs) are a reliable method for collecting patient data in osteoarthritis clinical trials and offer many advantages over paper collection; however,…
Abstract Number: 2374 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study
Hermine I. Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva⁴, Rayfel Schneider¹, Isabelle Kone-Paut², Kenneth Schikler¹, Katherine Marzan¹, Nico Wulffraat⁴, Shai Padeh⁴, Vyacheslav Chasnyk², Carine Wouters⁴, Jasmin B. Kuemmerle-Deschner⁴, Tilmann Kallinich⁴, Bernard Lauwerys⁵, Elie Haddad¹, Evgeny L Nasonov⁴, Maria Trachana⁴, Olga Vougiouka⁴, Karolynn Leon⁶, Antonio Speziale⁷, Karine Lheritier⁷, Eleni Vritzali⁸, Daniel J Lovell¹, Alberto Martini² and PRINTO/PRCSG, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Hôpital Necker-Enfants Malades, Paris, France, ⁴PRINTO-Istituto Gaslini, Genova, Italy, ⁵Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a highly selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic…
Abstract Number: 2375 • 2016 ACR/ARHP Annual Meeting
Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Grant Schulert¹, Francesca Minoia², John F. Bohnsack³, Randy Q. Cron⁴, Soah Hashad⁵, Isabelle Koné-Paut⁶, Mikhail Kostik⁷, Daniel J Lovell⁸, Despoina Maritsi⁹, Peter A. Nigrovic¹⁰, Priyankar Pal¹¹, Angelo Ravelli², Masaki Shimizu¹², Valda Stanevicha¹³, Bas Vastert¹⁴, Fabrizio De Benedetti¹⁵ and Alexei Grom¹⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁴Pediatric Rheumatology, Children's Hospital of Alabama, Birmingham, AL, ⁵Tripoli Children's Hospital, Tripoli, Libya, ⁶Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁷Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ⁸PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁹2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ¹⁰Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ¹¹Institute of Child Health, Kolkata, India, ¹²Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan, ¹³Pediatric cathedra, Riga Stradiņš University, Riga, Latvia, ¹⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening episode of hyperinflammation and a substantial cause of morbidity and mortality in pediatric rheumatology. It occurs most…
Abstract Number: 2376 • 2016 ACR/ARHP Annual Meeting
The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review
Susan Shenoi¹, Gerd Horneff², Michal Cidon³, Athimalaipet Ramanan⁴, Yukiko Kimura⁵, Pierre Quartier⁶, Ivan Foeldvari⁷, Andrew Zeft⁸, Kathleen G Lomax⁹, Jill Gregson¹⁰, Sarah Campbell¹¹, Jeffrey Weiss¹¹, Nina Marinsek¹¹, Dony Patel¹¹ and Nico Wulffraat¹², ¹Seattle Children's Hospital, Seattle, WA, ²Asklepios Kliniken GmbH, Hamburg, Germany, ³Stanford University, Palo Alto, CA, ⁴University Hospitals Bristol, Bristol, United Kingdom, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Hôpital Necker, Paris, France, ⁷Hamburger Zentrum für Kinder-und Jugend Rheumatologie, Hamburg, Germany, ⁸Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Navigant Consulting, Inc., London, United Kingdom, ¹²Wilhelmina Kinderziekenhuis, Utrecht, Netherlands
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe autoinflammatory disease characterized by systemic features including high fevers, rash, and arthritis. SJIA can impose a…
Abstract Number: 2377 • 2016 ACR/ARHP Annual Meeting
Innovative Use of PK and PD to Guide Dose Selection for a Monoclonal Antibody Aimed at Neutralizing the High IFNγ Activity Present in Patients with Macrophage Activation Syndrome (MAS)
Philippe Jacqmin¹, Kathy de Graaf², Maria Ballabio², Robert Nelson², Zoë Johnson², Walter Ferlin², Geneviève Lapeyre², Fabrizio De Benedetti³ and Cristina de Min², ¹MnS, Dinant, Belgium, ²NovImmune S.A., Geneva, Switzerland, ³Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy
Background/Purpose: Data from an animal model of MAS and the observed high IFNγ and IFNγ-related chemokines (CXCL9, CXCL10) levels in MAS/sJIA patients have prompted the…
Abstract Number: 2378 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial
Joost Frenkel¹, Jordi Anton², Avi Livneh³, Eldad Ben-Chetrit⁴, Paul Brogan⁵, Segundo Bujan-Rivas⁶, Tamás Constantin⁷, Fabrizio De Benedetti⁸, Marco Gattorno⁹, Ahmet Gül¹⁰, Hal M. Hoffman¹¹, Isabelle Kone-Paut¹², Helen Lachmann¹³, Seza Ozen¹⁴, Anna Simon¹⁵, Jeroen Van der Hilst¹⁶, Andrew Zeft¹⁷, Antonio Speziale¹⁸, Guido Junge¹⁸ and Lucy Xu¹⁹, ¹University Medical Center,Utrecht, Utrecht, Netherlands, ²Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, ³Department of Medicine F, Sheba Medical Center, Tel Hashomer, Israel, ⁴Medicine A Rheum Unit, Hadassah University Hosp, Jerusalem, Israel, ⁵Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁶Vall d'Hebron Hospital, Barcelona, Barcelona, Spain, ⁷Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ⁸Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ⁹UO Pediatria 2, Istituto Giannina Gaslini, Genova, Italy, ¹⁰Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹¹Pediatric Allergy, Immunology and Rheumatology, University of California at San Diego/Rady Children Hospital, La Jolla, CA, ¹²PRINTO, Genoa, Italy, ¹³UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁴Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁶Department of infectious disease and immunity, Jessa Hospital, Hasselt, Hasselt, Belgium, ¹⁷Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ¹⁸Novartis Pharma AG, Basel, Switzerland, ¹⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: The pharmacokinetics (PK) of canakinumab (CAN) and total interleukin (IL)-1β kinetics have been well investigated in CAPS patients (pts).1 Here we present the PK…
Abstract Number: 2379 • 2016 ACR/ARHP Annual Meeting
Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes
Anna Simon¹, Anna Shcherbina², Jordi Anton³, Eldad Ben-Chetrit⁴, Fabrizio De Benedetti⁵, Joost Frenkel⁶, Marco Gattorno⁷, Ryoki Hara⁸, Philip J Hashkes⁹, Michaël Hofer¹⁰, Hal M. Hoffman¹¹, Isabelle Koné-Paut¹², Helen Lachmann¹³, Alberto Martini¹⁴, Seza Ozen¹⁵, Andrew Zeft¹⁶, Antonio Speziale¹⁷, Guido Junge¹⁷ and Jill Gregson¹⁷, ¹General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Clinical immunology Department, Center of Children's Hematology n.a. D. Rogachev, Moscow, Russian Federation, ³Hospital Sant Joan de Déu, Barcelona, Spain, ⁴Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ⁵IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ⁶University Medical Center Utrecht, Utrecht, Netherlands, ⁷Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁸Yokohama City University, Yokohama, Japan, ⁹Pediatrics Rheumatology; Shaare-Zedek Medical Center, Jerusalem, Israel, ¹⁰Pediatric Rheumatology of Western Switzerland, CHUV, University of Lausanne, Lausanne, Switzerland, ¹¹University of California at San Diego, San Diego, CA, ¹²Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹³UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁴Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ¹⁵Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁶Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Open label studies have shown the efficacy of canakinumab (CAN), a fully human and highly specific anti-IL-1β monoclonal antibody, in patients (pts) with Periodic…
Abstract Number: 2380 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard Lauwerys⁴, Antonio Speziale⁵, Karolynn Leon⁶, Xiaoling Wei⁷ and Ronald Laxer⁸, ¹Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Shanghai Novartis Trading Limited, Shanghai, China, ⁸The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cryopyrin-Associated Periodic Syndrome (CAPS), is a rare hereditary auto inflammatory disorder representing 3 phenotypes: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic…
Abstract Number: 2381 • 2016 ACR/ARHP Annual Meeting
Canakinumab Monotherapy for the Treatment of Majeed Syndrome. Five-Year Experience
Mia Glerup¹, Bente Fiirgaard², Christian Høst³, Polly Ferguson⁴ and Troels Herlin⁵, ¹Pediatric Rheumatology Clinic, Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ²MR Research Centre, Aarhus University Hospital, Aarhus N, Denmark, ³Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Pediatrics--Rheumatology, University of Iowa Carver College of Medicine, Iowa City, IA, ⁵Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark
Background/Purpose: Majeed syndrome is a rare, autosomal recessive disorder that presents with early onset chronic recurrent multifocal osteomyelitis (CRMO) and microcytic congenital dyserythropoietic anaemia caused…
Abstract Number: 2382 • 2016 ACR/ARHP Annual Meeting
Evaluation of Intestinal Inflammation in Children with FMF
Ozge Altug-Gucenmez, Tuncay Kume, Balahan Makay, Omur Babayigit, Nur Arslan and Erbil Unsal, Dokuz Eylul University, Izmir, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease with recurrent fever and serositis episodes. Abnormal pyrin protein due to MEFV gene mutations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].